{"count": 1, "results": [{"_id": "21812893", "pmid": 21812893, "title": "Discordant effects on central obesity, hepatic insulin resistance, and alanine aminotransferase of low-dose metformin and thiazolidinedione combination therapy in patients with impaired glucose tolerance.", "journal": "Diabetes Obes Metab", "authors": ["Retnakaran R", "Ye C", "Hanley AJ", "Harris SB", "Zinman B"], "date": "2012-01-01T00:00:00Z", "doi": "10.1111/j.1463-1326.2011.01481.x", "meta_date_publication": "2012 Jan", "meta_volume": "14", "meta_issue": "1", "meta_pages": "91-3", "score": 50083.39, "text_hl": "In the Canadian Normoglycemia Outcome Evaluation trial, @CHEMICAL_Rosiglitazone @CHEMICAL_MESH:D000077154 @@@rosiglitazone@@@/@CHEMICAL_Metformin @CHEMICAL_MESH:D008687 @@@metformin@@@ (@<m>CHEMICAL_rosiglitazone_metformin_combination</m> @CHEMICAL_MESH:C471074 @@@Rosi/Met@@@, 4/1000 mg) reduced incident T2DM by 66% in subjects with @<m>DISEASE_Glucose_Intolerance</m> @DISEASE_MESH:D018149 @@@impaired glucose tolerance@@@. ", "citations": {"NLM": "Retnakaran R, Ye C, Hanley AJ, Harris SB, Zinman B. Discordant effects on central obesity, hepatic insulin resistance, and alanine aminotransferase of low-dose metformin and thiazolidinedione combination therapy in patients with impaired glucose tolerance. Diabetes Obes Metab. 2012 Jan;14(1):91-3. PMID: 21812893", "BibTeX": "@article{21812893, title={Discordant effects on central obesity, hepatic insulin resistance, and alanine aminotransferase of low-dose metformin and thiazolidinedione combination therapy in patients with impaired glucose tolerance.}, author={Retnakaran R and Ye C and Hanley AJ and Harris SB and Zinman B}, journal={Diabetes Obes Metab}, volume={14}, number={1}, pages={91-3}}"}}]}